An interval of fewer than 30 days between the last immunotherapy dose and the liver transplant increases the rejection risk ...
Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new ...
The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...
Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on Friday ...
In summary, adopting an active lifestyle to prevent obesity and related metabolic disorders, getting vaccinated for HBV, ...
Liver cancer often remains undetected until advanced stages. Learn about the causes and how you can protect yourself with ...
Discover the distinctive symptoms of liver pain, common underlying conditions, and effective treatment options to protect ...
A recent study unveils how stromal interaction molecule 1 (STIM1), a protein involved in calcium signaling, plays a pivotal ...
1d
Live Science on MSNThe rare genetic disorder that causes severe itchiness and liver failureAffected populations: PFIC is a group of rare genetic diseases that cause progressive liver failure. The exact prevalence of ...
23h
News-Medical.Net on MSNBreakthrough study defines ideal interval for immunotherapy and liver transplantsHepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new cases and 830,200 deaths were registered in 2020 according to the World ...
New research reveals distinct epidemiological trends in liver cancer across Mexico, with gender and regional variations ...
Liver cancer is the fourth most common cancer and the fourth leading cause of cancer-related deaths in the country.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results